Table 1.

Distributions of demographic data, tumor characteristics, treatment, and recurrence status by MRI use, among the women (age ≤ 50) diagnosed 2006–2013. Student’s t-tests were used for continuous variables and Pearson’s Chi-squared tests for categorical variables.

	MRI (330)	NO MRI (182)	P-value
Age	43.4 (5.0)	43.6 (5.2)	0.62
Race/ethnicity N (%)			0.65
Non-Hispanic white 379	244 (73.9%)	135 (74.2%)
Non-Hispanic black 70	45 (13.6%)	25 (13.7%)
Hispanic 30	18 (5.5%)	12 (6.6%)
Asian 16	13 (3.9%)	3 (1.6%)
Unknown 17	10 (3.0%)	7 (3.8%)
Tumor size (cm)	1.64 (1.2)	1.80 (1.3)	0.18
Grade N (%)			0.79
Grade 1 117	73 (22.1%)	44 (24.2%)
Grade 2 212	140 (42.4%)	72 (39.6%)
Grade 3 183	117 (35.5%)	66 (36.3%)
Histology N (%)			0.91
IDC 379	246 (74.5%)	133 (73.1%)
DCIS 110	69 (20.9%)	41 (22.5%)
ILC 23	15 (4.5%)	8 (4.4%)
Nodal status N (%)			0.55
Positive 145	97 (29.4%)	48 (26.4%)
Negative 296	185 (56.1%)	111 (61.0%)
Unknown 71	48 (14.5%)	23 (12.6%)
Tumor stage N (%)			0.80
Stage 0 110	69 (24.6%)	41 (26.1%)
Stage I 220	139 (49.5%)	81 (51.6%)
Stage II 61	40 (14.2%)	21 (13.4%)
Stage III 47	33 (11.7%)	66 (8.9%)
ER			0.98
Positive 415	267 (80.9%)	148 (81.3%)
Negative 89	58 (17.6%)	31 (17.0%)
Unknown 8	5 (1.5%)	3 (1.6%)
PR			0.96
Positive 399	256 (77.6%)	143 (78.6%)
Negative 107	70 (21.2%)	37 (20.3%)
Unknown 6	4 (1.2%)	2 (1.1%)
HER2			0.54
Positive 49	31 (9.4%)	18 (9.9%)
Negative 355	234 (70.9%)	121 (66.5%)
Unknown 108	65 (19.7%)	43 (23.6%)
Systemic treatment N (%)	294 (89.1%)	160 (87.9%)	0.69
Median diagnosis date	10/2008	08/2007
Follow-up length (years)	5.8 (2.6)	6.4 (2.6)	0.004
Re-excision	29 (8.8%)	21 (11.5%)	0.32
Local recurrence N (%)	26 (7.9%)	15 (8.2%)	0.88
Distant recurrence N (%)	21 (6.4%)	12 (6.6%)	0.92